$SUND
Sundance Strategies, Inc. Stock $sund

$sund Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000101041213000280 Filed on November 14, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2013 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$350.0K	$310.0K	$70.00K
YoY Change	1650.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$354.4K	$310.8K	$98.07K
YoY Change	2129.43%
Operating Profit	-$354.4K	-$310.8K	-$98.07K
YoY Change	2129.43%
Interest Expense	$31.02K	$30.71K	$6.577K
YoY Change	47623.08%
% of Operating Profit
Other Income/Expense, Net	$1.646M	-$30.71K	-$6.577K
YoY Change	-2532121.54%
Pretax Income	$1.291M	-$341.5K	-$104.7K
YoY Change	-6556.9%
Income Tax
% Of Pretax Income
Net Earnings	$1.291M	-$341.5K	-$104.7K
YoY Change	-8189.83%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$30.53K	-$8.045K	-$2.255K
COMMON SHARES
Basic Shares Outstanding	42.26M shares	42.26M shares	3.760M
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$120.0K	$980.0K	$550.0K
YoY Change
Cash & Equivalents	$124.9K	$979.6K	$545.4K
Short-Term Investments
Other Short-Term Assets			$0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$124.9K	$979.6K	$545.4K
YoY Change	34970.22%		220716.6%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$14.87M	$12.71M	$6.300M
YoY Change
Other Assets	$8.573M	$6.414M
YoY Change
Total Long-Term Assets	$15.74M	$12.71M	$6.299M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$124.9K	$979.6K	$545.4K
Total Long-Term Assets	$15.74M	$12.71M	$6.299M
Total Assets	$15.86M	$13.69M	$6.844M
YoY Change	4455667.42%		2770919.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.12K	$140.0K	$89.08K
YoY Change	82.88%		4689.35%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$3.000M	$3.000M
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$28.57K	$3.150M	$3.096M
YoY Change	-27.62%	15650.1%	19453.55%
LONG-TERM LIABILITIES
Long-Term Debt	$1.430M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$1.425M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.57K	$3.150M	$3.096M
Total Long-Term Liabilities	$1.425M	$0.00
Total Liabilities	$1.454M	$3.150M	$3.096M
YoY Change	3583.63%	15650.1%	19453.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$218.7K	-$1.510M	-$104.7K
YoY Change	-58.59%		-79.26%
Common Stock	$3.315M	$794.8K	$40.80K
YoY Change	88058.54%		985.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.41M	$10.54M	$3.749M
YoY Change
Total Liabilities & Shareholders Equity	$15.86M	$13.69M	$6.844M
YoY Change	4455667.42%		2770919.03%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2013 Q1
OPERATING ACTIVITIES
Net Income	$1.291M	-$341.5K	-$104.7K
YoY Change	-8189.83%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.450M	-$910.0K	-$3.323M
YoY Change		9000.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$860.0K
YoY Change
Cash From Investing Activities	-$860.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$3.869M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.460M	630.0K	$3.869M
YoY Change		6200.0%
NET CHANGE
Cash From Operating Activities	-2.450M	-910.0K	-$3.323M
Cash From Investing Activities	-860.0K
Cash From Financing Activities	2.460M	630.0K	$3.869M
Net Change In Cash	-850.0K	-280.0K	$545.4K
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$2.450M	-$910.0K	-$3.323M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001171838
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42261441	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	Sundance Strategies, Inc.
CY2013Q3	sund	Capitalized Consultant Fee CapitalizedConsultantFee	300000	USD
	sund	Fair Value Of Warrants Issued Stock Issuance Costs FairValueOfWarrantsIssuedStockIssuanceCosts	139251	USD
	sund	Fair Value Of Warrants Issued Stock Issuance Costs FairValueOfWarrantsIssuedStockIssuanceCosts	139251	USD
	sund	Life Insurance Policies Purchased With Debt LifeInsurancePoliciesPurchasedWithDebt		USD
	sund	Life Insurance Policies Purchased With Debt LifeInsurancePoliciesPurchasedWithDebt	2999000	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Expenses Plus Interest In Next Twelve Months LifeSettlementContractsInvestmentMethodExpensesPlusInterestInNextTwelveMonths	-2129869	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidAfterYearFive	-11647356	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFive	-2774967	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearFour	-3090988	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearThree	-2537915	USD
	sund	Life Settlement Contracts Investment Method Premiums Paid And Other Expenses LifeSettlementContractsInvestmentMethodPremiumsPaidAndOtherExpenses	22316954	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaid	-66239910	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid After Year Five LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidAfterYearFive	-31247030	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidInYearTwo	-3791449	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Expenses Plus Interest To Be Paid Total LifeSettlementContractsInvestmentMethodExpensesPlusInterestToBePaidTotal	-25972544	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInNextTwelveMonths	-6220069	USD
	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresWeightedAverageGrantDateFairValue		pure
	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2	P4Y9M18D
CY2013Q3	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	0.96	pure
CY2013Q3	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Five LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFive	-6591094	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearFour	-6982692	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearThree	-6994376	USD
CY2013Q3	sund	Life Settlement Contracts Investment Method Premiums Plus Expenses Plus Interest To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsPlusExpensesPlusInterestToBePaidInYearTwo	-8204649	USD
CY2013Q3	sund	Life Settlement Contracts Portion Of Pledge Agreement Paid In Cash LifeSettlementContractsPortionOfPledgeAgreementPaidInCash	3000000	USD
CY2013Q3	sund	Life Settlement Contracts Purchased Through Pledge Agreement LifeSettlementContractsPurchasedThroughPledgeAgreement	5999000	USD
CY2013Q2	sund	Maximum Number Of Common Shares Offered Through Private Placement MaximumNumberOfCommonSharesOfferedThroughPrivatePlacement	3000000	shares
	sund	Number Of Shares Of Restricted Stock Sold Through Private Placement NumberOfSharesOfRestrictedStockSoldThroughPrivatePlacement	1614500	shares
CY2013Q3	sund	Return Of Premium Provisions On Life Settlement Contracts ReturnOfPremiumProvisionsOnLifeSettlementContracts	326301	USD
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled Or Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledOrExpiredInPeriodIntrinsicValue		USD
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageRemainingContractualTerms
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms	P1Y11M1D
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value Extended ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValueExtended		USD
CY2013Q3	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePrice	5
CY2013Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedOutstandingWeightedAverageExercisePrice
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceForfeitures
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Exercise Price Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceGranted	5
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageExercisePrice	5
	sund	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm	P1Y8M
	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue		pure
	sund	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm2
CY2013Q1	sund	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue		pure
CY2013Q3	sund	Stock Issuance Costs Payable StockIssuanceCostsPayable	585000	USD
CY2013Q3	sund	Total Cash Consideration That Would Be Paid By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalCashConsiderationThatWouldBePaidByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	8000000	USD
CY2013Q3	sund	Total Consideration That Would Be Paid By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalConsiderationThatWouldBePaidByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	20000000	USD
CY2013Q3	sund	Total Notes Payable That Would Be Issued By Company If All Net Insurance Benefits Are Provided Under Asset Transfer Agreement TotalNotesPayableThatWouldBeIssuedByCompanyIfAllNetInsuranceBenefitsAreProvidedUnderAssetTransferAgreement	12000000	USD
CY2013Q3	sund	Value Of Net Insurance Benefits Required To Be Delivered Per Asset Transfer Agreement ValueOfNetInsuranceBenefitsRequiredToBeDeliveredPerAssetTransferAgreement	400000000	USD
CY2013Q4	sund	Value Of Net Insurance Benefits Required To Be Delivered Per Asset Transfer Agreement ValueOfNetInsuranceBenefitsRequiredToBeDeliveredPerAssetTransferAgreement	400000000	USD
CY2013Q3	sund	Working Capital WorkingCapital	2170462	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	143578	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	89082	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11263661	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3850257	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	752500	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock		USD
CY2013Q3	us-gaap	Assets Assets	13692620	USD
CY2013Q1	us-gaap	Assets Assets	6844417	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	979557	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	545417	USD
CY2013Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	12713063	USD
CY2013Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	6299000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	979557	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	545417	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	434140	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	979557	USD
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	5
CY2013Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	139251	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42261441	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40797441	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42261441	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40797441	shares
CY2013Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	20000	shares
CY2013Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	170500	shares
CY2013Q3	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	100000	USD
CY2013Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	2000000	USD
CY2013Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	3000000	USD
CY2013Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	1500000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	42261	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	40798	USD
CY2013Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2999000	USD
CY2013Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2999999	USD
CY2013Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.04	pure
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2013-12-31
CY2013Q4	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1717022	USD
CY2013Q4	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	8241319	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div style="WIDTH: 660px"><!--StartFragment--> <p style="MARGIN: 0px; text-align: justify"><strong>(2) NEW ACCOUNTING PRONOUNCEMENTS</strong></p> <p style="MARGIN: 0px; text-align: justify"><br /> </p> <p style="MARGIN: 0px; text-align: justify; TEXT-INDENT: 48px">The Company has reviewed recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.</p> <!--EndFragment--></div> </div>
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2013Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	374931	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1101756	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	186681	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1155658	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1405435	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-341518	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1510086	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14496	USD
	us-gaap	Interest Expense InterestExpense	60782	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo	-4413200	USD
CY2013Q4	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	2000000	USD
CY2013Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	1500000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	95824	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	6414063	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	6414063	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3300000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	30709	USD
	us-gaap	Interest Expense InterestExpense	67359	USD
	us-gaap	Interest Income Other InterestIncomeOther	21	USD
CY2013Q3	us-gaap	Interest Income Other InterestIncomeOther		USD
	us-gaap	Interest Income Other InterestIncomeOther	21	USD
CY2013Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	67359	USD
CY2013Q3	us-gaap	Liabilities Liabilities	3150019	USD
CY2013Q1	us-gaap	Liabilities Liabilities	3095523	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13692620	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6844417	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	15195	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3150019	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3095523	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	6299000	USD
CY2013Q1	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	6299000	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	129365234	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing After Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingAfterYearFive	113365234	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths		USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Five LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFive	16000000	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Four LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour		USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Three LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree		USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo		USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid	-40267366	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	22	pure
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing After Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingAfterYearFive	18	pure
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths		pure
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Five LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFive	4	pure
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour		pure
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Three LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree		pure
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo		pure
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid After Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidAfterYearFive	-19599674	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths	-4090200	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Five LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFive	-3816127	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Four LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearFour	-3891704	USD
CY2013Q3	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree	-4456461	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7579275	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11448015	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7145135	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10468458	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1405435	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-341518	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1510086	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-60761	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30709	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-67338	USD
CY2013Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2999000	USD
CY2013Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2999000	USD
CY2013Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	3441	USD
CY2013Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	3441	USD
	us-gaap	Operating Expenses OperatingExpenses	1344674	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	310809	USD
	us-gaap	Operating Expenses OperatingExpenses	1442748	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1344674	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-310809	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1442748	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6414063	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		USD
CY2013Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4000	USD
CY2013Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	25000	USD
CY2013Q3	us-gaap	Other Notes Payable OtherNotesPayable	12000000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	545000	USD
CY2013Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	520000	USD
CY2013Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	6400	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	24000000	USD
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties		USD
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties		USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6826775	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10695515	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	8072500	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	752500	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	752500	USD
	us-gaap	Professional Fees ProfessionalFees	242918	USD
CY2013Q3	us-gaap	Professional Fees ProfessionalFees	124128	USD
	us-gaap	Professional Fees ProfessionalFees	287090	USD
CY2013Q3	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	5735	USD
CY2013Q1	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	37510	USD
	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	4000000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1510086	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104651	USD
	us-gaap	Revenues Revenues		USD
CY2013Q3	us-gaap	Revenues Revenues		USD
	us-gaap	Revenues Revenues		USD
	us-gaap	Share Based Compensation ShareBasedCompensation	659867	USD
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.1	pure
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		USD
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested		USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	70000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.96
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.96
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y8M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	70000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.96
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	70000	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	463029
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1785000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.96
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7550550	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1785000	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.77
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y6M14D
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4536675	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1072500	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.77
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y6M14D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.96
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	400000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.77
CY2013Q3	us-gaap	Share Price SharePrice	5
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	10542601	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	3748894	USD
	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	5735	USD
	us-gaap	Stock Issued During Period Shares Issued For Cash StockIssuedDuringPeriodSharesIssuedForCash	150500	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares Issued For Cash StockIssuedDuringPeriodSharesIssuedForCash	1384000	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	1464000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	752500	USD
CY2013Q4	us-gaap	Stock Issued During Period Value Issued For Cash StockIssuedDuringPeriodValueIssuedForCash	6920000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	7320000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	659867	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	659867	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41781441	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42261441	shares

Files In Submission

Name	View Source	Status
0001010412-13-000280-index-headers.html	Edgar Link	pending
0001010412-13-000280-index.html	Edgar Link	pending
0001010412-13-000280.txt	Edgar Link	pending
0001010412-13-000280-xbrl.zip	Edgar Link	pending
ex311.htm	Edgar Link	pending
ex312.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mpearsonssiemploymentagre001.jpg	Edgar Link	pending
mpearsonssiemploymentagre002.jpg	Edgar Link	pending
mpearsonssiemploymentagre003.jpg	Edgar Link	pending
mpearsonssiemploymentagre004.jpg	Edgar Link	pending
mpearsonssiemploymentagre005.jpg	Edgar Link	pending
mpearsonssiemploymentagre006.jpg	Edgar Link	pending
mpearsonssiemploymentagre007.jpg	Edgar Link	pending
mpearsonssiemploymentagre008.jpg	Edgar Link	pending
mpearsonssiemploymentagre009.jpg	Edgar Link	pending
mpearsonssiemploymentagre010.jpg	Edgar Link	pending
mpearsonssiemploymentagre011.jpg	Edgar Link	pending
mpearsonssiemploymentagreeme.htm	Edgar Link	pending
qtr209301312lwbcleanwithallc.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sund-20130930.xml	Edgar Link	completed
sund-20130930.xsd	Edgar Link	pending
sund-20130930_cal.xml	Edgar Link	unprocessable
sund-20130930_def.xml	Edgar Link	unprocessable
sund-20130930_lab.xml	Edgar Link	unprocessable
sund-20130930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SUND
Sundance Strategies, Inc. Stock $sund

2013 Q4 Form 10-Q Financial Statement

#000101041213000280 Filed on November 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUND Sundance Strategies, Inc. Stock $sund

2013 Q4 Form 10-Q Financial Statement

#000101041213000280 Filed on November 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SUND
Sundance Strategies, Inc. Stock $sund